A detailed history of Mutual Of America Capital Management LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Mutual Of America Capital Management LLC holds 1,924 shares of ALNY stock, worth $474,843. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,924
Previous 1,519 26.66%
Holding current value
$474,843
Previous $369,000 43.36%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$233.81 - $287.01 $94,693 - $116,239
405 Added 26.66%
1,924 $529,000
Q4 2023

Jan 26, 2024

SELL
$151.41 - $196.57 $25,436 - $33,023
-168 Reduced 9.96%
1,519 $290,000
Q2 2023

Aug 11, 2023

BUY
$185.01 - $212.05 $9,990 - $11,450
54 Added 3.31%
1,687 $320,000
Q4 2022

Feb 10, 2023

SELL
$185.53 - $241.31 $14,285 - $18,580
-77 Reduced 4.5%
1,633 $388,000
Q3 2022

Nov 08, 2022

BUY
$138.54 - $232.0 $236,903 - $396,720
1,710 New
1,710 $342,000
Q2 2021

Aug 06, 2021

SELL
$128.63 - $176.89 $239,637 - $329,546
-1,863 Closed
0 $0
Q1 2021

May 13, 2021

SELL
$126.83 - $175.69 $7,229 - $10,014
-57 Reduced 2.97%
1,863 $263,000
Q4 2020

Feb 12, 2021

SELL
$122.97 - $147.0 $13,280 - $15,876
-108 Reduced 5.33%
1,920 $250,000
Q2 2020

Aug 06, 2020

BUY
$104.21 - $156.44 $54,710 - $82,131
525 Added 34.93%
2,028 $300,000
Q4 2019

Feb 11, 2020

SELL
$74.51 - $124.23 $17,062 - $28,448
-229 Reduced 13.22%
1,503 $173,000
Q1 2019

May 13, 2019

SELL
$72.76 - $93.45 $14,770 - $18,970
-203 Reduced 10.49%
1,732 $162,000
Q2 2018

Aug 09, 2018

BUY
$88.31 - $107.8 $84,777 - $103,488
960 Added 98.46%
1,935 $191,000
Q1 2018

May 11, 2018

BUY
$115.92 - $148.54 $113,022 - $144,826
975 New
975 $116,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.4B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Mutual Of America Capital Management LLC Portfolio

Follow Mutual Of America Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mutual Of America Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mutual Of America Capital Management LLC with notifications on news.